Sandoz has resolved its Hatch-Waxman patent-infringement dispute with AbbVie in the US over the originator’s Rinvoq (upadacitinib) extended-release tablets, declaring that its proposed abbreviated new drug application product infringes 23 patents shielding the mega-blockbuster JAK inhibitor.
According to a stipulation and order signed by Delaware district court judge Maryellen Noreika, “Sandoz admits that the asserted patents...
Welcome to Generics Bulletin
Create an account to read this article
Already a subscriber?